Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), filed a Form 4 on August 26, 2026, disclosing the sale of 3,035 shares of common stock on August 24, 2026, pursuant to a Rule 10b5-1 automatic sale instruction to satisfy tax withholding obligations.

Key Highlights

  • Shares sold: Peter Kaiser disposed of 3,035 shares of Ocular Therapeutix common stock on August 24, 2026.
  • Weighted average price: Shares were sold at a weighted average price of $10.77, with individual transactions ranging from $10.6429 to $10.9125, inclusive.
  • Purpose: According to the filing, the sale was a sell-to-cover to satisfy tax withholding obligations connected to the vesting of restricted stock units on August 22, 2026.
  • Rule 10b5-1 plan: The sales were executed under a durable automatic sale instruction adopted by Kaiser on April 9, 2024, and the filing states "the sales do not represent a discretionary trade by the reporting person."
  • Remaining ownership: Following the transaction, Kaiser beneficially owned 264,378 shares of common stock directly.
  • ESPP shares included: The post-transaction total includes 1,272 shares acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

Details of Peter Kaiser's Sell-to-Cover Transaction at Ocular Therapeutix

According to the Form 4 filed with the SEC on August 26, 2026, Peter Kaiser, serving as Chief Development Officer of Ocular Therapeutix, Inc., sold 3,035 shares of the company's common stock on August 24, 2026. The filing identifies the transaction code as "S" and classifies the shares as disposed of (D) under a direct ownership form. The sale was carried out under a durable automatic sale instruction Kaiser adopted on April 9, 2024, qualifying the transaction under Rule 10b5-1(c).

The filing reports a weighted average sale price of $10.77 per share, with individual transactions executed at prices ranging from $10.6429 to $10.9125, inclusive. The filing states that Kaiser "undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price." The purpose of the sale, as described in the filing, was to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026.

Following the reported transaction, Kaiser's direct beneficial ownership stood at 264,378 shares of common stock, a figure that the filing notes includes 1,272 shares acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Todd Anderman as Attorney-in-Fact for Peter Kaiser.

What Was Disclosed

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, disclosed the sale of 3,035 common shares on August 24, 2026, at a weighted average price of $10.77, executed as a sell-to-cover for RSU vesting tax obligations under a pre-established Rule 10b5-1 plan, leaving him with 264,378 shares.